Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid plus teriparatide versus teriparatide alone in postmenopausal women with severe osteoporosis
2006-000861-12Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zoledronic acid and teriparatide in osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Percentage increase in lumbar spine bone mineral density at 52 weeks. Started Dec 2006; status: completed.
02
Drugs
zoledronic acidteriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2006-000861-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000861-12.